JPWO2020011724A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020011724A5 JPWO2020011724A5 JP2021500279A JP2021500279A JPWO2020011724A5 JP WO2020011724 A5 JPWO2020011724 A5 JP WO2020011724A5 JP 2021500279 A JP2021500279 A JP 2021500279A JP 2021500279 A JP2021500279 A JP 2021500279A JP WO2020011724 A5 JPWO2020011724 A5 JP WO2020011724A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- pharmaceutical composition
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 108090001123 antibodies Proteins 0.000 claims description 9
- 102000004965 antibodies Human genes 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 241000658540 Ora Species 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 150000002825 nitriles Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 2
- 125000005842 heteroatoms Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000611 antibody drug conjugate Substances 0.000 claims 11
- 108091008116 antibody drug conjugates Proteins 0.000 claims 11
- 102100006815 IL2RA Human genes 0.000 claims 8
- 101700082799 IL2RA Proteins 0.000 claims 8
- 101700015336 ISG20 Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229960005277 gemcitabine Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 206010024324 Leukaemias Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 2
- 210000004214 Philadelphia Chromosome Anatomy 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229920002574 CR-39 Polymers 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 200000000028 growth disorder Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000004882 non-tumor cells Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 108060005723 speA Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811364.7A GB201811364D0 (en) | 2018-07-11 | 2018-07-11 | Combination therapy |
| GB1811364.7 | 2018-07-11 | ||
| PCT/EP2019/068287 WO2020011724A1 (en) | 2018-07-11 | 2019-07-08 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533090A JP2021533090A (ja) | 2021-12-02 |
| JPWO2020011724A5 true JPWO2020011724A5 (ko) | 2022-07-19 |
Family
ID=63272970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500279A Pending JP2021533090A (ja) | 2018-07-11 | 2019-07-08 | 併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230132256A1 (ko) |
| EP (1) | EP3820478A1 (ko) |
| JP (1) | JP2021533090A (ko) |
| KR (1) | KR20210031696A (ko) |
| CN (1) | CN112367999A (ko) |
| AU (1) | AU2019301850A1 (ko) |
| BR (1) | BR112021000456A2 (ko) |
| CA (1) | CA3101703A1 (ko) |
| EA (1) | EA202092824A1 (ko) |
| GB (1) | GB201811364D0 (ko) |
| IL (1) | IL279908A (ko) |
| MX (1) | MX2020013446A (ko) |
| PH (1) | PH12021550035A1 (ko) |
| SG (1) | SG11202012401RA (ko) |
| UA (1) | UA126313C2 (ko) |
| WO (1) | WO2020011724A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| GB202015916D0 (en) * | 2020-10-07 | 2020-11-18 | Adc Therapeutics Sa | Combination therapy |
| WO2022248268A1 (en) * | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Ｃｄ25에 대한 인간 모노클로날 항체 |
| CN109053523B (zh) | 2005-10-07 | 2022-03-25 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
| ES2653617T3 (es) * | 2011-02-02 | 2018-02-08 | Ashland Licensing And Intellectual Property, Llc | Recubrimiento de gel resistente al rayado |
| NZ707543A (en) * | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| ES2680153T3 (es) * | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| JP6878287B2 (ja) | 2014-11-25 | 2021-05-26 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン−抗体コンジュゲート |
| GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201507827D0 (en) * | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
-
2018
- 2018-07-11 GB GBGB1811364.7A patent/GB201811364D0/en not_active Ceased
-
2019
- 2019-07-08 US US17/259,466 patent/US20230132256A1/en active Pending
- 2019-07-08 MX MX2020013446A patent/MX2020013446A/es unknown
- 2019-07-08 SG SG11202012401RA patent/SG11202012401RA/en unknown
- 2019-07-08 BR BR112021000456-4A patent/BR112021000456A2/pt not_active Application Discontinuation
- 2019-07-08 UA UAA202008232A patent/UA126313C2/uk unknown
- 2019-07-08 WO PCT/EP2019/068287 patent/WO2020011724A1/en active Application Filing
- 2019-07-08 EP EP19742541.6A patent/EP3820478A1/en not_active Withdrawn
- 2019-07-08 KR KR1020217001943A patent/KR20210031696A/ko unknown
- 2019-07-08 JP JP2021500279A patent/JP2021533090A/ja active Pending
- 2019-07-08 AU AU2019301850A patent/AU2019301850A1/en not_active Abandoned
- 2019-07-08 CN CN201980045650.9A patent/CN112367999A/zh active Pending
- 2019-07-08 CA CA3101703A patent/CA3101703A1/en active Pending
- 2019-07-08 EA EA202092824A patent/EA202092824A1/ru unknown
-
2020
- 2020-12-31 IL IL279908A patent/IL279908A/en unknown
-
2021
- 2021-01-06 PH PH12021550035A patent/PH12021550035A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518741A5 (ko) | ||
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| JP2018502902A5 (ko) | ||
| TW202218685A (zh) | 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物 | |
| JP6557744B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| ES2808565T3 (es) | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib | |
| JP2018516243A5 (ko) | ||
| JP2017515802A5 (ko) | ||
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| JP2018511628A5 (ko) | ||
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2018531278A6 (ja) | 癌のための併用療法 | |
| JP2018531278A (ja) | 癌のための併用療法 | |
| JP2021169511A (ja) | 免疫療法用組み合わせ組成物 | |
| KR20080048489A (ko) | 신규 항암 병용제 | |
| JP7479292B2 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| JPWO2020011724A5 (ko) | ||
| JP2016540826A5 (ko) | ||
| TW201343169A (zh) | 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法 | |
| JPWO2019224275A5 (ko) | ||
| KR20210142700A (ko) | 항종양 조성물 | |
| JP7154634B2 (ja) | 腫瘍免疫賦活剤 | |
| JP2020527594A5 (ko) |